Insmed reported $2.23B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
DBV Technologies USD 215.4M 7.8M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Insmed USD 2.23B 123.49M Sep/2026
Novartis USD 117.15B 1.38B Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026